{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:22:36Z","timestamp":1766514156679,"version":"3.44.0"},"reference-count":18,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,2,26]]},"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:p>An extremely premature baby boy born at 23 weeks\u2019 gestational age was treated with unilateral low dose of 0.16 mg\/0.025\u2009mL intravitreal bevacizumab in the left eye for aggressive retinopathy of prematurity (ROP). He developed photographically documented changes in his contralateral right eye on imaging 5 days later. Second eye treatment was at 12 days. He has development assessment and ophthalmic review beyond age 2, which is normal. Systemic absorption of the drug caused an end organ effect to slow down and reverse ROP in his untreated right eye. Both eyes vascularised fully. His normal Bayley III developmental score at age 2 is uncommon for a 23-week gestation baby. Even at a low dose, bevacizumab has the potential for end organ effect on the second eye, and therefore other organs. In this case, there are no medium-term measurable neurodevelopmental side-effects. We suggest longer term follow-up is required before excluding unwanted side-effects.<\/jats:p>","DOI":"10.1136\/bcr-2019-232359","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T05:15:12Z","timestamp":1584076512000},"page":"e232359","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Contralateral effect of systemic absorption of low dose bevacizumab (Avastin) after unilateral intravitreal injection in severe retinopathy of prematurity (ROP)"],"prefix":"10.1136","volume":"13","author":[{"given":"Ayad","family":"Shafiq","sequence":"first","affiliation":[{"name":"Ophthalmology, Royal Victoria Infirmary, Newcastle, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxane","family":"Hillier","sequence":"additional","affiliation":[{"name":"Ophthalmology, Royal Victoria Infirmary, Newcastle, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Hearn","sequence":"additional","affiliation":[{"name":"Royal Victoria Infirmary, Newcastle upon Tyne, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"key":"2025082703253322000_13.3.e232359.1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-15842"},{"key":"2025082703253322000_13.3.e232359.2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"2025082703253322000_13.3.e232359.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.07.005"},{"key":"2025082703253322000_13.3.e232359.4","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaophthalmol.2013.400","article-title":"Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity","volume":"131","author":"Karaca","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"2025082703253322000_13.3.e232359.5","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-310408"},{"key":"2025082703253322000_13.3.e232359.6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.4103\/ijo.IJO_2115_18","article-title":"The safety and effectiveness of 0.16 Mg bevacizumab plus or minus additional laser photocoagulation in the treatment of retinopathy of prematurity","volume":"67","author":"Akdogan","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"2025082703253322000_13.3.e232359.7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11845-017-1684-y","article-title":"Ultra-Low dose of intravitreal bevacizumab in retinopathy of prematurity","volume":"187","author":"\u015eahin","year":"2018","journal-title":"Ir J Med Sci"},{"key":"2025082703253322000_13.3.e232359.8","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"W-C","year":"2017","journal-title":"Retina Phila Pa"},{"key":"2025082703253322000_13.3.e232359.9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"},{"key":"2025082703253322000_13.3.e232359.10","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of lower doses of Intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study","volume":"135","author":"Wallace","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"2025082703253322000_13.3.e232359.11","doi-asserted-by":"crossref","unstructured":"Morin J , Luu TM , Superstein R , et al . Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics 2016;137. doi:doi:10.1542\/peds.2015-3218","DOI":"10.1542\/peds.2015-3218"},{"key":"2025082703253322000_13.3.e232359.12","doi-asserted-by":"crossref","unstructured":". Mart\u00ednez-Castellanos MA , Schwartz S , Hern\u00e1ndez-Rojas ML , et al . Long-Term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up: retina 2013;33:329\u201338.","DOI":"10.1097\/IAE.0b013e318275394a"},{"key":"2025082703253322000_13.3.e232359.13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3928\/23258160-20190605-01","article-title":"Neurodevelopmental outcomes comparing bevacizumab to laser for type 1 ROP","volume":"50","author":"Rodriguez","year":"2019","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2025082703253322000_13.3.e232359.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment","volume":"11","author":"Lien","year":"2016","journal-title":"PLoS One"},{"key":"2025082703253322000_13.3.e232359.15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaapos.2017.10.006","article-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","volume":"22","author":"Kennedy","year":"2018","journal-title":"J Aapos"},{"key":"2025082703253322000_13.3.e232359.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374"},{"key":"2025082703253322000_13.3.e232359.17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000449530","article-title":"The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity: a comparison study between ranibizumab and bevacizumab","volume":"236","author":"Alyama\u00e7 Sukgen","year":"2016","journal-title":"Ophthalmologica"},{"key":"2025082703253322000_13.3.e232359.18","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","article-title":"Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial","volume":"172","author":"Stahl","year":"2018","journal-title":"JAMA Pediatr"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-232359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:25:40Z","timestamp":1756290340000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-232359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3,12]]},"published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1136\/bcr-2019-232359"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-232359","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}